Immortals Review: Following the GLP-1 Care Path From Intake to Delivery

A telehealth prescription is a chain of responsibilities, not simply an online purchase. Someone evaluates the intake, a clinician decides whether to prescribe, a pharmacy dispenses the medicine, and a delivery service transports it. Immortals describes several links in that chain, including physician review and ongoing messaging. The most useful way to assess its GLP-1 offering is to follow those handoffs—and identify where a prospective patient still needs a name, a written term or a practical answer.

Immortals presents itself as a longevity-focused telehealth platform offering compounded semaglutide and tirzepatide alongside branded products. This review examines public documentation consulted October 19, 2026, rather than firsthand treatment or independent verification of clinical credentials. The documented pathway has useful features, including approval before charging and access to physician messaging. Its limitations include unidentified dispensing pharmacies, different review-time estimates and member prices whose full cost cannot be established without the membership terms.

At a glance

Entry into care: Adults 18 and older in eligible U.S. states can complete an intake advertised as taking 5–10 minutes; a physician reviews every case before prescribing.
Sources: [6]
Review and shipping clocks: The collection page describes review typically within 24 hours; product pages say within 72 hours. Most medicines are advertised to ship 2–5 business days after review and prescribing.
Sources: [6] [7]
Compounded products: Immortals advertises injectable compounded tirzepatide and semaglutide with glycine and B12, and states that its compounded formulations are not FDA approved.
Sources: [7] [10] [6]
Conditional member pricing: Advertised member totals include $217/month for compounded tirzepatide and $167/month for compounded semaglutide, billed quarterly with a three-month commitment paid upfront. Membership cost is not established.
Sources: [7] [10]
After purchase: The medicine policy says all sales are final, with no returns or refunds, and directs customers to contact the company about suspected prescription-filling errors.
Sources: [8]

Start by identifying who is responsible for care

Immortals Medicine describes itself as a platform connecting patients with licensed physicians who may prescribe medication protocols after assessment. Prescriptions are explicitly not guaranteed. Its general terms identify Continuance LLC and subsidiaries as the operator of services under Immortals and other brands. The website attributes the founding of Immortals and Blueprint to Bryan Johnson and Kate Tolo, but brand leadership is not the same thing as responsibility for a particular patient's consultation.

The website presents Carl Seger, M.D., as a board-certified physician specializing in preventive and longevity medicine. Those are provider statements, not credentials independently verified for this review. More importantly for the care pathway, the consulted documentation does not identify the clinical entity responsible for consultations and prescriptions or name the dispensing pharmacies. Before proceeding, request the identity of the treating practice and the pharmacy that would handle the prescribed product.

This distinction matters if an intake needs clarification, a prescription contains an error or a shipment arrives damaged. A platform can coordinate those steps without performing all of them itself. Our guide to the clinician–platform distinction explains why patients should know which organization handles medical decisions and which handles account support. Immortals documents physician involvement, but that does not by itself resolve every operational responsibility.

Sources: [9] [12] [6]

The intake is brief; the prescribing decision is separate

Immortals advertises a 5–10-minute intake covering medical history, current medications, goals and treatment preferences. It says a physician reviews every case before any prescription is issued. Product pages describe review by a U.S.-licensed, board-certified physician, and some states may require a synchronous audio or video consultation before approval. Completing the questionnaire therefore starts an assessment; it is not equivalent to receiving a prescription or securing a particular medicine.

The medicine program is advertised for adults 18 and older in eligible U.S. states, with additional restrictions depending on the medication. The personalized tirzepatide page says the product is not recommended for people with a personal or family history of medullary thyroid cancer or MEN2, and that the physician will assess whether it is appropriate. Although the general terms list services in all 50 states, that broader statement does not establish access to every product everywhere. The consulted pages do not provide a medication-by-state list or establish the service's BMI thresholds. Confirm availability for the exact product and state rather than relying on the national service list.

For practical preparation, bring an accurate medication and supplement list and questions about how follow-up will work. NIDDK describes medication selection as a discussion of health conditions, other medicines, side effects, benefits and costs. That framework complements the advertised questionnaire without predicting eligibility. Our first-consultation preparation guide can help organize questions; the treating clinician, not a product selector or review, makes the individual prescribing decision.

Sources: [6] [9] [7] [2]

Confirm the exact product before the pharmacy handoff

Immortals lists compounded tirzepatide with glycine and B12 and compounded semaglutide with the same additives, describing both personalized products as weekly injectables. The tirzepatide page also displays personalized-dose and microdose options. Those labels document choices in the storefront, not evidence that a particular option is appropriate or produces a particular outcome. The visible material does not establish which variant or supply quantity corresponds to every displayed price.

The branded listings add another layer of presentation checking. Wegovy is identified as semaglutide, with tablet and injection options, but the extracted pricing text does not unambiguously tie the amount to either presentation. The Zepbound KwikPen listing identifies tirzepatide as a weekly injection. Immortals also presents Foundayo as orforglipron in a daily oral tablet. These are descriptions of its listings, not independent confirmation of regulatory status, inventory or availability for a particular patient.

Immortals acknowledges that compounded formulations are not FDA approved. FDA recommends compounded drugs when an individual's medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence. Still, ingredient names do not resolve formulation, concentration, presentation or dispensing responsibility. The pharmacy-handoff checklist offers a useful structure for obtaining those details before a prescription is filled.

Sources: [7] [10] [6] [5] [4] [3] [1]

Approval comes before charging, but the monthly figures carry conditions

The collection page says pricing varies by medication and dose, insurance is not required, and patients are charged only after physician approval. The tirzepatide page also says membership fees are not required to obtain treatment. That statement can coexist with optional member discounts, but it does not establish the complete cost of joining. The table distinguishes the displayed subtotal from the conditional member figure rather than treating the lower number as an unconditional monthly plan.

Every member amount below carries the stated condition: quarterly billing with a three-month commitment paid upfront. The documentation does not establish the membership price or its complete terms, so these figures cannot determine the total program cost. Nor does the commitment establish how many containers, pens or other units are supplied. For Wegovy specifically, the presentation associated with the displayed price remains unresolved.

Before approval triggers a charge, request an itemized amount showing the prescribed formulation and presentation, membership charges if selected, and whether video consultations, shipping, injection supplies or necessary testing cost extra. Immortals advertises no hidden fees, but the consulted material does not establish those inclusions product by product. Similarly, no insurance requirement does not confirm insurance billing, coverage or prior-authorization assistance. General terms also allow applicable taxes and transaction fees.

Displayed medicine pricing. All member figures require quarterly billing and a three-month commitment paid upfront; membership cost is not established.
Listed product	Displayed subtotal	Conditional member amount
Compounded tirzepatide with glycine and B12; injectable	$255/month	$217/month
Compounded semaglutide with glycine and B12; injectable	$196/month	$167/month
Wegovy; priced tablet or injection presentation unresolved	$1,550/month	$1,317/month
Zepbound KwikPen; tirzepatide injection	$600/month	$510/month
Foundayo; listed as orforglipron oral tablet	$750/month	$637/month

Sources: [6] [7] [10] [5] [4] [3] [9]

Review, dispatch and arrival run on different clocks

Immortals gives several timing estimates that should not be collapsed into one promise. The collection page says physician review is typically completed within 24 hours, while product pages say within 72 hours. The collection also says most medicines ship in 2–5 business days once reviewed and prescribed. A product-page headline describes the overall journey from intake to the door as three to seven days. These are provider estimates, not independently measured delivery performance.

The important distinction is between a review decision, shipment and actual arrival. A package that ships within an advertised window has not necessarily arrived within that window. Immortals advertises direct-to-door delivery in discreet packaging, but the consulted documentation does not specify the carrier, tracking arrangements, refrigeration requirements or procedures for delay, loss and damage. Ask when tracking becomes available and which contact handles a package problem after the pharmacy releases it.

For injectable deliveries, FDA explicitly recommends not using a GLP-1 drug that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy to resolve the concern. That advice should remain separate from any advertised delivery speed. Our explanation of warm-delivery and cold-chain concerns provides context. The missing handling details are a reason to obtain instructions before shipment, not evidence that a particular Immortals package would be mishandled.

Sources: [6] [7] [1]

Messaging access needs a practical follow-up plan

The product page advertises unlimited physician messaging, says the doctor is available through chat for additional support, and notes available video consultations alongside an “up to 12 months” label. This is useful documentation of a contact pathway. It does not specify a response deadline, appointment frequency, whether the same physician continues care or whether every video visit is included in the medication charge. Messaging access should not be read as a promise of immediate clinical response.

Before starting, ask how scheduled reviews differ from patient-initiated messages, who reviews treatment response and how prescription renewals are authorized. NIDDK describes follow-up as attention to response and tolerability, not merely ongoing payment. FDA also reports measurement and administration errors involving compounded drugs, some associated with hospitalization. Patients should clarify instructions with their prescriber or pharmacist rather than derive measurements from a review, product comparison or online discussion.

Immortals' longevity framing does not change those responsibilities. The terms warn that its AI tools do not provide medical advice and may be inaccurate. An app-generated protocol or automated explanation is therefore not a substitute for the clinician's instructions or the dispensing pharmacy's clarification. A useful onboarding answer would explain where to send medical questions, where to report a dispensing issue and which communication channel handles ordinary account or billing requests.

Sources: [7] [9] [2] [1]

Keep biomarker testing separate from the medication pathway

Immortals sells a separate Biomarker Tests subscription for $365 annually. Its stated inclusions are two comprehensive blood panels and urine tests per year, more than 100 unique biomarkers, at least 160 measurements and access to the Biomarkers platform. Initial and follow-up appointments are scheduled through that platform at local Quest Diagnostics laboratories. These are documented features of a testing subscription, not proof that these tests are included in a GLP-1 prescription price or required for every medication patient.

Testing also has its own geography and timing. Customers must be at least 18 and based in the United States; the page excludes Arizona, Hawaii, New Jersey, New York and Rhode Island. Its FAQ says 95% receive full results within two weeks, despite a separate “Results in a Week” headline. The two-week figure is a provider claim about laboratory results, not medication delivery. Do not substitute the general 50-state service list for these explicit testing restrictions.

The homepage describes the app and uploading outside biomarker results as free, with testing, prescriptions and supplements optional. However, it also contains a “COMING SOON” app reference, leaving actual availability unclear. For biomarker HSA/FSA reimbursement, the page describes an eligibility review and, if approved, a medical-necessity letter in one to two days for submission with a receipt. That is a reimbursement pathway, not guaranteed payment or evidence of medication coverage.

Sources: [11] [12]

Plan the next prescription—and the exit—before the first charge

General subscription terms provide for automatic renewal and require cancellation at least 24 hours before the current period ends to avoid the next cycle's subscription charge. Cancellation is available through account settings and becomes effective at the end of the current period, stopping future charges. The consulted material does not clearly explain how those general provisions apply to every medicine plan or prescription renewal. Obtain the specific renewal date and applicable notice deadline in writing.

The medicine-specific policy says sales are final and that returns and refunds are unavailable, while inviting contact about suspected prescription-filling errors. General terms also contemplate legal exceptions and discretionary refunds, but cancellation itself does not promise money back. For an upfront three-month commitment, that distinction is especially material. Before paying, ask what happens to already collected charges if the clinician changes the plan, a dispensing problem occurs or the patient chooses not to continue.

Sources: [8] [9]

Questions & answers

Does completing Immortals' intake guarantee a prescription?

No. Immortals says a physician reviews every case and prescriptions depend on assessment. The advertised intake takes 5–10 minutes, and some states may require an audio or video consultation before approval. The platform also limits medicine access to eligible states, with restrictions varying by product. Confirm the exact medicine's availability rather than treating a completed questionnaire as approval.

Sources: [6] [7]

Must I buy an Immortals membership to receive treatment?

The tirzepatide page says membership fees are not required to access treatment. However, lower displayed prices are member offers, and the consulted documentation does not establish the membership's price or complete conditions. Those discounted medicine figures require quarterly billing and a three-month commitment paid upfront. Ask for both the nonmember treatment terms and the complete member checkout total.

Sources: [7]

Which pharmacy fills Immortals prescriptions?

The consulted public documentation does not name the dispensing pharmacies. Immortals describes its compounded products as coming from licensed pharmacies, but that statement does not identify who will fill an individual prescription. Request the pharmacy's name, contact details and exact product information before dispensing, along with instructions for reporting a filling error or delivery concern.

Sources: [6] [8]

How soon should I expect medicine to arrive?

Immortals advertises an overall intake-to-door estimate of three to seven days, but separately describes review typically within 24 hours on the collection page and within 72 hours on product pages. Most medicines are said to ship 2–5 business days after review and prescribing. Shipping is not arrival; ask for the actual dispatch status, tracking and expected delivery date.

Sources: [6] [7]

Does Immortals include ongoing physician support?

Its product page advertises unlimited physician messaging and available video consultations, with an “up to 12 months” label. It does not establish a response-time commitment or clarify whether every video consultation is included in each medicine price. Ask how routine monitoring, urgent questions and renewal decisions are handled, rather than assuming unlimited messaging means immediate or fully scheduled care.

Sources: [7]

Will cancelling my subscription produce a refund?

Not automatically. General terms say account-setting cancellation stops future charges and takes effect at the current period's end, with at least 24 hours' notice required to avoid the next subscription charge. The medicine policy says sales are final without returns or refunds. Confirm how cancellation applies to the specific medicine plan; do not equate stopping renewal with reversing an upfront payment.

Sources: [9] [8]

Our assessment

Immortals documents a recognizable care pathway: a structured intake, physician assessment before charging, prescription-dependent delivery and ongoing messaging. It also distinguishes its compounded products from FDA-approved preparations and publishes meaningful payment and refund conditions. Those are useful starting points, not a complete account of care delivery. The unresolved issues sit at important handoffs: the responsible clinical entity, named pharmacy, exact supplied presentation, complete member cost, delivery-problem procedures and practical follow-up schedule. A prospective patient should obtain those details before approval triggers payment, especially when selecting a quarterly, upfront member offer. The platform's longevity branding and broader testing ecosystem do not establish outcomes for its medication program. The strongest basis for a decision is a clear, product-specific explanation of who provides care, what is dispensed, what is charged and who remains responsible afterward.

Visit Immortals’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

FOLLOW THE EVIDENCE

Research behind treatment claims

Use these studies to assess the type of outcome a treatment claim describes. They did not test this provider or establish results for its products.

SURMOUNT-5: What a Direct Weight-Loss Comparison Can—and Cannot—Tell You About Ongoing Care
Tirzepatide produced greater average weight and waist reductions than semaglutide over 72 weeks. Understanding the trial’s design matters just as much as understanding the difference.
After the Weight Loss: What SURMOUNT-4 Means for Continuity of Care
Randomized tirzepatide withdrawal separates maintaining a treatment effect from finishing a course. Reading its two baselines—and newer maintenance-dose research—shows what the evidence can and cannot tell patients changing care.

Explore the science library →

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Immortals Review: Following the GLP-1 Care Path From Intake to Delivery

At a glance

01Start by identifying who is responsible for care

02The intake is brief; the prescribing decision is separate

03Confirm the exact product before the pharmacy handoff

04Approval comes before charging, but the monthly figures carry conditions

05Review, dispatch and arrival run on different clocks

06Messaging access needs a practical follow-up plan

07Keep biomarker testing separate from the medication pathway

08Plan the next prescription—and the exit—before the first charge